Pancreatic Neoplasms (Pancreatic Cancer)

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Also Known As:

Pancreatic Cancer; Cancer of the Pancreas; Neoplasm, Pancreatic; Pancreas Cancer; Neoplasms, Pancreatic; Pancreas Neoplasms; Pancreatic Acinar Carcinoma; Pancreatic Carcinoma; Acinar Carcinoma, Pancreatic; Acinar Carcinomas, Pancreatic; Cancer, Pancreas; Cancer, Pancreatic; Cancers, Pancreas; Cancers, Pancreatic; Carcinoma, Pancreatic; Carcinoma, Pancreatic Acinar; Carcinomas, Pancreatic; Carcinomas, Pancreatic Acinar; Neoplasm, Pancreas; Neoplasms, Pancreas; Pancreas Cancers; Pancreas Neoplasm; Pancreatic Acinar Carcinomas; Pancreatic Cancers; Pancreatic Carcinomas; Pancreatic Neoplasm; Cancer of Pancreas

Networked: 35273 relevant articles (2775 outcomes, 7770 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Pain (Aches)
4.	Pancreatic Neoplasms (Pancreatic Cancer)
5.	Adenocarcinoma

Experts

1.	Maitra, Anirban: 187 articles (04/2024 - 04/2002)
2.	Büchler, Markus W: 186 articles (12/2023 - 01/2002)
3.	Saif, Muhammad Wasif: 163 articles (01/2021 - 07/2005)
4.	Friess, Helmut: 158 articles (10/2023 - 01/2002)
5.	Hruban, Ralph H: 137 articles (05/2024 - 01/2002)
6.	Abbruzzese, James L: 125 articles (01/2020 - 01/2002)
7.	Yu, Xianjun: 122 articles (12/2024 - 03/2002)
8.	Evans, Douglas B: 115 articles (12/2023 - 01/2002)
9.	Hoffman, Robert M: 110 articles (01/2024 - 04/2002)
10.	Kleeff, Jörg: 109 articles (01/2024 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pancreatic Neoplasms:

1.	Gemcitabine FDA Link 01/01/2009 - "Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. " 10/26/2021 - "Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. " 09/01/2012 - "Gemcitabine is currently the best treatment available for pancreatic cancer (PaCa); however, patients with the disease develop resistance to the drug over time. " 05/01/2011 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but causes high toxicity. " 04/15/2007 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease develops resistance to the drug over time. "
2.	130-nm albumin-bound paclitaxelIBA 08/01/2016 - "Nab-paclitaxel has recently been described to be beneficial in metastatic pancreatic cancer improving overall and progression free survival (PFS). " 10/21/2016 - "The phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall survival, the primary endpoint. " 07/01/2022 - "It is recommended to maintain a sufficient RDI of nab-paclitaxel to ensure that the balance between lerability, therapeutic efficacy, and survival benefits is satisfied in patients with advanced pancreatic cancer." 07/01/2022 - "Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study." 07/01/2022 - "However, few studies have focused on the efficacy of the RDI of nab-paclitaxel in patients with advanced pancreatic cancer, and whether the RDI of nab-paclitaxel could be employed as an index for treatment remains unknown. "
3.	Fluorouracil (Carac)FDA LinkGeneric 04/01/1992 - "Our preliminary data suggest that biochemical modulation of 5-FU with FA and IFN-alpha (reduced dosage) is effective in pancreatic cancer with moderate toxicity, warranting further study." 01/01/2023 - "In conclusion, these findings suggest that the synergistic properties of TTF and 5-FU result in greater therapeutic efficacy against pancreatic cancer cells than either modality alone and may improve survival rates in patients with pancreatic cancer." 09/07/2019 - "The purpose of this single-center, retrospective, cohort study was to determine if nal-iri/5FU and FOLFIRI are similarly effective for the treatment of advanced pancreatic cancer. " 11/15/2021 - "Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model." 02/01/2010 - "The efficacy of 5-FU may be lower in pancreatic cancer tissue than in normal tissue because DPD activity is upregulated in pancreatic cancer tissue compared to normal pancreatic tissue. "
4.	folfirinoxIBA 01/01/2023 - "FOLFIRINOX, used in metastatic pancreatic cancer (MPC), is highly efficacious but also toxic. " 11/01/2017 - "FOLFIRINOX is now considered to be a highly effective regimen for patients with metastatic pancreatic cancer. " 01/01/2014 - "FOLFIRINOX appeared to be the best regimen for advanced pancreatic cancer probabilistically, with a trend towards improvement in survival when compared with other regimens by indirect comparisons." 01/01/2021 - "Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status." 01/01/2021 - "Modified FOLFIRINOX (mFOLFIRINOX) appears to be a better-tolerated regimen, which leads to improved survival in metastatic pancreatic cancer that has histological and molecular similarities with BTC. "
5.	Biomarkers (Surrogate Marker)IBA 01/01/2015 - "This study opens up an interesting avenue of investigation to potentially identify predictive biomarkers and novel therapeutic targets for pancreatic cancer, a disease that has seen no significant improvement in survival over the past 40 years." 04/01/2024 - "In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. " 01/01/2012 - "In order to achieve a better outcome for pancreatic cancer patients, reliable biomarkers are required which allow for improved diagnosis. " 03/01/2004 - "If pancreatic cancer could be diagnosed more readily and accurately using serum markers, patient survival could theoretically be improved by enabling more patients to avail of surgical resection. " 02/01/1999 - "However, the improvement in diagnostic accuracy is still not satisfactory in spite of an elaborate combination of serum markers in diagnosis for pancreatic cancer. "
6.	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/09/2011 - "The CAF-AsPC-1 pancreatic cancer xenografts reached significantly greater tumour volume than those xenografts lacking CAF and were resistant to the anti-tumour effects of EGFR inhibition with erlotinib. " 01/01/2018 - "Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer." 11/01/2013 - "We evaluated the efficacy of erlotinib plus GEM in patients with unresectable pancreatic cancer. " 04/01/2021 - "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial." 03/26/2021 - "The aim of this study was to evaluate whether knockdown of DJ-1 expression can sensitize pancreatic cancer cells to erlotinib treatment. "
7.	Irinotecan (Camptosar)FDA LinkGeneric 03/01/2007 - "Single-agent irinotecan has significant efficacy for metastatic pancreatic cancer. " 05/07/2007 - "To confirm the efficacy of PMX-CPT-11 combination, we extended the study to a panel of 10 pancreatic cancer cell lines using clinically relevant concentrations (PMX 10 microM; CPT-11 1 microm). " 01/01/2019 - "Irinotecan (IRI) is a widely used chemotherapeutic drug, mostly used for first-line treatment of colorectal and pancreatic cancer. " 05/10/2024 - "Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis." 01/01/2024 - "Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear."
8.	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/01/2004 - "It is hypothesized that well designed, personalized, molecular-based treatments may improve the efficacy of oxaliplatin for the treatment of colorectal, gastric and pancreatic cancer. " 05/07/2023 - "In this study, we explored the anticancer efficacy and mechanism of KV in oxaliplatin-resistant pancreatic cancer cells and patient-derived pancreatic cancer organoids (PDPCOs) with KRAS mutation. " 09/05/2022 - "Thirty-four patients (M/F:22/12) who underwent liver MRI-MRE and received oxaliplatin for colorectal, gastric, and pancreas cancer were included in the study. " 05/20/2005 - "Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer. " 01/01/2005 - "A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. "
9.	Leucovorin (Folinic Acid)FDA Link 09/01/1998 - "However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. " 09/01/1997 - "Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. " 01/01/1996 - "The purpose of this study was to test the effectiveness of the oral combination with dFUR plus l-leucovorin in gastric and pancreatic cancer patients. " 07/03/2018 - "The results suggested that the use of IRI-FP-Folinic Acid scheme in the second-line treatment of metastatic pancreatic cancer may offer a benefit in terms of OS and PFS for patients not previously treated with these drugs." 12/01/2005 - "Between 1994 and 2003, 68 patients with non-resectable pancreas cancer TNM stage III and IV, were enrolled to receive intraperitoneal5-FU instillation 750-1500 mg/m2 and intravenous Leucovorin 100 mg/m2 for two days every third week. "
10.	Proteins (Proteins, Gene)FDA Link 04/01/2007 - "Thus, targeted degradation of Sp proteins is highly effective for inhibiting VEGFR1 and associated angiogenic responses in pancreatic cancer." 05/01/2000 - "The results confirm the potential therapeutic efficacy of FTI treatment in pancreatic cancer, and suggest that farnesylated proteins other than K-Ras may act as important regulators of G2/M cell cycle kinetics." 10/01/1997 - "Western blot analysis showed that transfection of AS-K-ras-LNSX led to a significant reduction in the amounts of Ki-ras p21 protein in all the pancreatic cancer cell lines except BxPC-3. " 11/01/2019 - "In this study, we evaluated the therapeutic efficacy of a newly developed mAb targeting microfibril-associated protein 5 (MFAP5), which is secreted predominately by cancer-associated fibroblast (CAF), in ovarian and pancreatic cancer models.Experimental" 06/13/2020 - "Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model."

Therapies and Procedures

1.	Therapeutics 12/01/2023 - "The abovementioned substances/medications are the most popular or potentially effective in PC treatment and consequently CAM-based adjuvant therapy through improving patients' quality of life, might be a useful addition in the treatment of pancreatic cancer patients." 07/06/2021 - "With the development of new chemotherapeutic agents and introduction of multidisciplinary therapy, however, the treatment outcomes for pancreatic cancer have dramatically improved over the past two decades. " 04/01/2019 - "Most patients have lost the opportunity for surgery when they are diagnosed,which resulted in an urgent need for the development of more effective and safe therapies for pancreatic cancer. " 01/01/2019 - "Altogether, these results suggest that combination therapy consisting of Gem followed by TKH2-conjugated CDDP NGs induces highly synergistic therapeutic efficacy against pancreatic cancer. " 04/01/2014 - "Currently, the best treatment for locally advanced pancreatic cancer is considered to be safe and effective surgery, followed by appropriate additional therapies implemented as quickly as possible. "
2.	Drug Therapy (Chemotherapy) 10/01/2021 - "Complete surgical resection, most often associated with perioperative chemotherapy, is the only way to offer a chance of cure for patients with pancreatic cancer. " 07/01/2017 - "Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?" 01/01/2008 - "Which is the best monitoring modality to evaluate the efficacy of chemotherapy on unresectable pancreatic cancer ? " 01/01/2006 - "Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. " 01/01/2023 - "This case is rare, and there are few reports of complete remission after chemotherapy for pancreatic cancer. "
3.	Radiotherapy 03/27/2019 - "Moreover, most of previous studies only adopted conventional radiotherapy as the neoadjuvant modality though stereotactic body radiation therapy (SBRT) has been proven effective and commonly employed in pancreatic cancer. " 11/01/2008 - "3-D conformal gamma-knife radiotherapy combined with thermochemotherapy is well tolerated and is relatively effective for most patients with locally advanced pancreatic cancer." 01/01/2022 - "Local control in borderline resectable pancreatic cancer is likely improved with radiation therapy; however, the benefit of improved local control in a disease marked by systemic failure has been questioned. " 10/01/2011 - "Thus, strategies to improve the efficacy of radiotherapy in pancreatic cancer are important to pursue. " 01/01/2017 - "Ablative radiation therapy can be beneficial for pancreatic cancer, and motion mitigation helps to reduce dose to nearby organs-at-risk. "
4.	Neoadjuvant Therapy 06/01/2019 - "The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. " 01/01/2022 - "Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes." 06/01/2017 - "The efficacy of neoadjuvant chemoradiotherapy (NACRT) for resectable and borderline resectable pancreatic cancer is important for predicting outcomes after radical surgery, but few clinical indicators predict outcome before resection. " 02/15/2016 - "Neoadjuvant chemoradiation for locally-advanced, primarily non- or borderline resectable pancreas cancer results in secondary resectability in a substantial proportion of patients with consecutively markedly improved overall prognosis and should be considered as possible alternative in pretreatment multidisciplinary evaluations. " 12/01/2015 - "Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles."
5.	Immunotherapy 12/01/2022 - "The efficacy of conventional treatments for pancreatic cancer remains unsatisfactory, and immunotherapy is an emerging option for adjuvant treatment of this highly deadly disorder. " 01/01/2018 - "While most of the clinical trial results are still being awaited, several intrinsic features of pancreatic cancer such as low mutational load and the presence of highly immunosuppressive desmoplasia significantly hamper the efficacy of immunotherapy in this disease. " 01/01/2023 - "This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. " 10/01/2019 - "To our knowledge, this is the first to report advanced pancreatic cancer with mismatch repair proficiency had a good response to immunotherapy, and this is the first to report an association between high blood-based TMB or NLR and improved clinical outcomes in pancreatic cancer. " 09/03/2021 - "This study systematically investigated the potential effectiveness of a novel pancreatic cancer immunotherapy targeting RTKs, and revealed the function of MET in PD-L1 regulation as well as the combined therapeutic efficacy of MET and PD-L1 in pancreatic cancer."